Clinical Trial Update: ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib [Phase 3]

View source ↗

Summary

Phase 3 trial for ErbB2-overexpressing metastatic breast cancer using paclitaxel, trastuzumab, and lapatinib; study terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neoplasms

Drugs mentioned

• Lapatinib (Lapatinib)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Breast | Phase 3 | Status: TERMINATED | Results posted: 2014-08-20